Targeted Next-Generation Sequencing for Improved Clinical Outcomes in People Living With Rare Diseases in Global South: Protocol for a Systematic Review and Meta-Synthesis
JMIR Research Protocols · 03.07.2026 · 15 · e85150
DOI: 10.2196/85150 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JMIR Research Protocols, online erschienen am 03.07.2026. Verfasst von Mapaseka Seheri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diarrheal Pathogens Research Unit (DPRU), Department of Medical Virology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, G…. Hauptthemen laut MEDLINE: Rare Diseases, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Rare diseases affect many individuals and pose major challenges in diagnosis and treatment, especially in Global South countries where health care resources are limited. Targeted next-generation sequencing (NGS) has significantly advanced diagnostic accuracy and clinical care for rare diseases globally; however, its implementation and impact within the Global South context remain insufficiently studied.
Objective
This study aims to evaluate the use, clinical benefits, challenges, and implementation outcomes of targeted NGS for diagnosing and managing rare diseases in Global South populations. Specifically, it seeks to quantify the diagnostic yield of NGS, examine its influence on subsequent clinical decision-making, and identify principal barriers to, and facilitators of, the implementation of targeted NGS approaches in these contexts.
Methods
This protocol follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We will systematically search PubMed, Scopus, and Web of Science for studies published between 2005 and 2025 that report on the use of targeted NGS in Global South population with rare diseases. Two reviewers will independently perform study selection, data extraction, quality assessment, and evaluation of risk of bias by using QUADAS-2 for diagnostic accuracy studies and the risk of bias assessment tool for nonrandomized studies. Meta-analyses will be conducted to estimate pooled outcomes for diagnostic yield, with heterogeneity assessed using random effects models. Heterogeneity will be further examined through visual inspection of forest plots and by evaluating the chi-square test and I² statistic.
Results
The protocol has been registered with PROSPERO (CRD420251078455). Database search or screening, data extraction, and data synthesis are planned to commence in June 2026 and conclude by September 2026. Study findings will synthesize the diagnostic yield, clinical impact, and contextual determinants influencing the implementation of targeted NGS in Global South health care settings.
Conclusions
This review will provide evidence on the application, advantages, limitations, and clinical outcomes of targeted NGS for individuals affected by rare diseases in countries of the Global South. The finding will identify priorities for capacity strengthening, policy development, and future genomic research. Trial Registration PROSPERO CRD420251078455; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251078455 International Registered Report Identifier (IRRID) PRR1-10.2196/85150
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diarrheal Pathogens Research Unit (DPRU), Department of Medical Virology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa.
- Department of Paediatrics and Child Health, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa.
- Electron Microscope Unit, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa.
- Department of Nephrology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa.
- Department of Public Health, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa.
- SAMRC/SMU Public Health Interventions, Innovations and lmplementation Research Unit, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa.
ORCID-Profile: Mapaseka Seheri, Dini Mawela, Lerato Kgosana, Chantelle Baker, Wesley Van Hougenhouck-Tulleken, Olanrewaju Oladimeji
Zitieren
APA
Seheri, M., Mawela, D., Kgosana, L., Baker, C., Van Hougenhouck-Tulleken, W., & Oladimeji, O. (2026). Targeted Next-Generation Sequencing for Improved Clinical Outcomes in People Living With Rare Diseases in Global South: Protocol for a Systematic Review and Meta-Synthesis. JMIR Research Protocols, 15, e85150. https://doi.org/10.2196/85150
Vancouver
Seheri M, Mawela D, Kgosana L, Baker C, Van Hougenhouck-Tulleken W, Oladimeji O. Targeted Next-Generation Sequencing for Improved Clinical Outcomes in People Living With Rare Diseases in Global South: Protocol for a Systematic Review and Meta-Synthesis. JMIR Research Protocols. 2026;15:e85150. doi:10.2196/85150
BibTeX
@article{Seheri2026,
author = {Seheri, Mapaseka and Mawela, Dini and Kgosana, Lerato and Baker, Chantelle and Van Hougenhouck-Tulleken, Wesley and Oladimeji, Olanrewaju},
title = {Targeted Next-Generation Sequencing for Improved Clinical Outcomes in People Living With Rare Diseases in Global South: Protocol for a Systematic Review and Meta-Synthesis},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e85150},
doi = {10.2196/85150}
}
EUVIMED